Insmed to Present at Two October Conferences

BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will participate in the following investor conferences:

• The Cantor Fitzgerald Global Healthcare Conference in New York City on Monday, October 1, 2018 at 4:40 p.m. ET.
• The Leerink Partners Roundtable Series: Rare Disease & Oncology in New York City on Tuesday, October 2, 2018 at 1:30 p.m. ET.

These presentations will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcasts will be archived for a period of 90 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.  For more information, visit www.insmed.com.

Contact:Blaine Davis Insmed Incorporated (908) 947-2841 [email protected]

You May Also Be Interested In

• Cantor Fitzgerald Reiterates Overweight Rating on Insmed (INSM) Ahead of Q2 Results
• FG Communities Completes Acquisition in Wilkesboro, NC
• BlockDAG Unlocks $0.00000015 Entry Price, & 30% Live Swap Discount, While Cardano & XRP Target Breakouts